You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Association between genomic recurrence risk and well-being among breast cancer patients
|
|---|---|
| Published in |
BMC Cancer, June 2013
|
| DOI | 10.1186/1471-2407-13-295 |
| Pubmed ID | |
| Authors |
Valesca P Retèl, Catharina GM Groothuis-Oudshoorn, Neil K Aaronson, Noel T Brewer, Emiel JT Rutgers, Wim H van Harten |
| Abstract |
BACKGROUND: Gene expression profiling (GEP) is increasingly used in the rapidly evolving field of personalized medicine. We sought to evaluate the association between GEP-assessed of breast cancer recurrence risk and patients' well-being. METHODS: Participants were Dutch women from 10 hospitals being treated for early stage breast cancer who were enrolled in the MINDACT trial (Microarray In Node-negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy). As part of the trial, they received a disease recurrence risk estimate based on a 70-gene signature and on standard clinical criteria as scored via a modified version of Adjuvant! Online. \Women completed a questionnaire 6--8 weeks after surgery and after their decision regarding adjuvant chemotherapy. The questionnaire assessed perceived understanding, knowledge, risk perception, satisfaction, distress, cancer worry and health-related quality of life (HRQoL), 6--8 weeks after surgery and decision regarding adjuvant chemotherapy. RESULTS: Women (n = 347, response rate 62%) reported high satisfaction with and a good understanding of the GEP information they received. Women with low risk estimates from both the standard and genomic tests reported the lowest distress levels. Distress was higher predominately among patients who had received high genomic risk estimates, who did not receive genomic risk estimates, or who received conflicting estimates based on genomic and clinical criteria. Cancer worry was highest for patients with higher risk perceptions and lower satisfaction. Patients with concordant high-risk profiles and those for whom such profiles were not available reported lower quality of life. CONCLUSION: Patients were generally satisfied with the information they received about recurrence risk based on genomic testing. Some types of genomic test results were associated with greater distress levels, but not with cancer worry or HRQoL.Trial registration: ISRCTN: ISRCTN18543567. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 1 | 33% |
| Practitioners (doctors, other healthcare professionals) | 1 | 33% |
| Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 83 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 83 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 12% |
| Student > Master | 10 | 12% |
| Other | 8 | 10% |
| Student > Ph. D. Student | 7 | 8% |
| Unspecified | 5 | 6% |
| Other | 18 | 22% |
| Unknown | 25 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 19% |
| Agricultural and Biological Sciences | 7 | 8% |
| Psychology | 7 | 8% |
| Nursing and Health Professions | 6 | 7% |
| Unspecified | 5 | 6% |
| Other | 13 | 16% |
| Unknown | 29 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 June 2013.
All research outputs
#15,557,505
of 23,881,329 outputs
Outputs from BMC Cancer
#3,807
of 8,483 outputs
Outputs of similar age
#120,138
of 199,270 outputs
Outputs of similar age from BMC Cancer
#48
of 80 outputs
Altmetric has tracked 23,881,329 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,483 research outputs from this source. They receive a mean Attention Score of 4.4. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 199,270 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 80 others from the same source and published within six weeks on either side of this one. This one is in the 36th percentile – i.e., 36% of its contemporaries scored the same or lower than it.